Advice
following a full submission
entecavir (Baraclude®) is not recommended for use within NHS Scotland.
Indication under review: treatment of chronic hepatitis B virus (HBV) infection in adults with decompensated liver disease.
Entecavir demonstrated a superior virological response in adults with chronic HBV and decompensated liver disease compared with another nucleoside/nucleotide analogue. However there is no comparative evidence versus the relevant comparator.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice132KB (PDF)
Medicine details
- Medicine name:
- entecavir (Baraclude)
- SMC ID:
- 747/11
- Indication:
- Treatment of chronic hepatitis B infection in adults with decompensated liver disease
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 16 January 2012